Skip to main content
NewslettersWatchlist

Corbus Pharmaceuticals Hldgs Inc(CRBP-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low34.24
Day High38.44
Open:37.97
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
TheNewswire.com
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
PR Newswire
Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
PR Newswire
Corbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
PR Newswire
Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting
PR Newswire
Corbus Pharmaceuticals Data on CRB-601 avฮฒ8 Blocking Antibody Accepted for Presentation at the America Association for Cancer Research Annual Meeting
PR Newswire
Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update
PR Newswire
Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA
PR Newswire
Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC)
PR Newswire
Corbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
PR Newswire
Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
PR Newswire
Corbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
PR Newswire
Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors
PR Newswire
Corbus Pharmaceuticals to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference
AccessWire
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
Globe NewsWire
Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
Globe NewsWire
Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
Globe NewsWire
Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases
Globe NewsWire
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress
Globe NewsWire
CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING
Globe NewsWire
Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates
Globe NewsWire
Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences
Globe NewsWire
Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)
Globe NewsWire
Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
Globe NewsWire
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results
Globe NewsWire
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
Globe NewsWire
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021
Globe NewsWire
Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases
Globe NewsWire
Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
Globe NewsWire
Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates
Globe NewsWire
Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis
Globe NewsWire
Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020
Globe NewsWire
Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020

Profile

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright ยฉ 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright ยฉ 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.